Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure

Background Sodium‐glucose cotransporter 2 inhibitors improve cardiovascular outcomes in patients with diabetes with and without heart failure (HF). However, their influence on sympathetic nerve activity (SNA) remains unclear. The purpose of this study was to evaluate the effect of sodium‐glucose cot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takuto Hamaoka, Hisayoshi Murai, Tadayuki Hirai, Hiroyuki Sugimoto, Yusuke Mukai, Oto Inoue, Shinichiro Takashima, Takeshi Kato, Shigeo Takata, Soichiro Usui, Kenji Sakata, Masa‐Aki Kawashiri, Masayuki Takamura
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	baroreflex sensitivity diabetes mellitus heart failure muscle sympathetic nerve activity Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d3f18ed3b0f44bb7bd18790cbe50b31c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d3f18ed3b0f44bb7bd18790cbe50b31c
record_format	dspace
spelling	oai:doaj.org-article:d3f18ed3b0f44bb7bd18790cbe50b31c2021-11-16T10:22:43ZDifferent Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure10.1161/JAHA.121.0226372047-9980https://doaj.org/article/d3f18ed3b0f44bb7bd18790cbe50b31c2021-11-01T00:00:00Zhttps://www.ahajournals.org/doi/10.1161/JAHA.121.022637https://doaj.org/toc/2047-9980Background Sodium‐glucose cotransporter 2 inhibitors improve cardiovascular outcomes in patients with diabetes with and without heart failure (HF). However, their influence on sympathetic nerve activity (SNA) remains unclear. The purpose of this study was to evaluate the effect of sodium‐glucose cotransporter 2 inhibitors on SNA and compare the responses of SNA to sodium‐glucose cotransporter 2 inhibitors in patients with type 2 diabetes with and without HF. Methods and Results Eighteen patients with type 2 diabetes, 10 with HF (65.4±3.68 years) and 8 without HF (63.3±3.62 years), were included. Muscle SNA (MSNA), heart rate, and blood pressure were recorded before and 12 weeks after administration of dapagliflozin (5 mg/day). Sympathetic and cardiovagal baroreflex sensitivity were simultaneously calculated. Brain natriuretic peptide level increased significantly at baseline in patients with HF than those without HF, while MSNA, blood pressure, and hemoglobin A1c did not differ between the 2 groups. Fasting blood glucose and homeostatic model assessment of insulin resistance did not change in either group after administering dapagliflozin. MSNA decreased significantly in both groups. However, the reduction in MSNA was significantly higher in patients with HF than patients with non‐HF (−20.2±3.46 versus −9.38±3.65 bursts/100 heartbeats; P=0.049), which was concordant with the decrease in brain natriuretic peptide. Conclusions Dapagliflozin significantly decreased MSNA in patients with type 2 diabetes regardless of its blood glucose‐lowering effect. Moreover, the reduction in MSNA was more prominent in patients with HF than in patients with non‐HF. These results indicate that the cardioprotective effects of sodium‐glucose cotransporter 2 inhibitors may, in part, be attributed to improved SNA.Takuto HamaokaHisayoshi MuraiTadayuki HiraiHiroyuki SugimotoYusuke MukaiOto InoueShinichiro TakashimaTakeshi KatoShigeo TakataSoichiro UsuiKenji SakataMasa‐Aki KawashiriMasayuki TakamuraWileyarticlebaroreflex sensitivitydiabetes mellitusheart failuremuscle sympathetic nerve activityDiseases of the circulatory (Cardiovascular) systemRC666-701ENJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 22 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	baroreflex sensitivity diabetes mellitus heart failure muscle sympathetic nerve activity Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	baroreflex sensitivity diabetes mellitus heart failure muscle sympathetic nerve activity Diseases of the circulatory (Cardiovascular) system RC666-701 Takuto Hamaoka Hisayoshi Murai Tadayuki Hirai Hiroyuki Sugimoto Yusuke Mukai Oto Inoue Shinichiro Takashima Takeshi Kato Shigeo Takata Soichiro Usui Kenji Sakata Masa‐Aki Kawashiri Masayuki Takamura Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure
description	Background Sodium‐glucose cotransporter 2 inhibitors improve cardiovascular outcomes in patients with diabetes with and without heart failure (HF). However, their influence on sympathetic nerve activity (SNA) remains unclear. The purpose of this study was to evaluate the effect of sodium‐glucose cotransporter 2 inhibitors on SNA and compare the responses of SNA to sodium‐glucose cotransporter 2 inhibitors in patients with type 2 diabetes with and without HF. Methods and Results Eighteen patients with type 2 diabetes, 10 with HF (65.4±3.68 years) and 8 without HF (63.3±3.62 years), were included. Muscle SNA (MSNA), heart rate, and blood pressure were recorded before and 12 weeks after administration of dapagliflozin (5 mg/day). Sympathetic and cardiovagal baroreflex sensitivity were simultaneously calculated. Brain natriuretic peptide level increased significantly at baseline in patients with HF than those without HF, while MSNA, blood pressure, and hemoglobin A1c did not differ between the 2 groups. Fasting blood glucose and homeostatic model assessment of insulin resistance did not change in either group after administering dapagliflozin. MSNA decreased significantly in both groups. However, the reduction in MSNA was significantly higher in patients with HF than patients with non‐HF (−20.2±3.46 versus −9.38±3.65 bursts/100 heartbeats; P=0.049), which was concordant with the decrease in brain natriuretic peptide. Conclusions Dapagliflozin significantly decreased MSNA in patients with type 2 diabetes regardless of its blood glucose‐lowering effect. Moreover, the reduction in MSNA was more prominent in patients with HF than in patients with non‐HF. These results indicate that the cardioprotective effects of sodium‐glucose cotransporter 2 inhibitors may, in part, be attributed to improved SNA.
format	article
author	Takuto Hamaoka Hisayoshi Murai Tadayuki Hirai Hiroyuki Sugimoto Yusuke Mukai Oto Inoue Shinichiro Takashima Takeshi Kato Shigeo Takata Soichiro Usui Kenji Sakata Masa‐Aki Kawashiri Masayuki Takamura
author_facet	Takuto Hamaoka Hisayoshi Murai Tadayuki Hirai Hiroyuki Sugimoto Yusuke Mukai Oto Inoue Shinichiro Takashima Takeshi Kato Shigeo Takata Soichiro Usui Kenji Sakata Masa‐Aki Kawashiri Masayuki Takamura
author_sort	Takuto Hamaoka
title	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure
title_short	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure
title_full	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure
title_fullStr	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure
title_full_unstemmed	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure
title_sort	different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/d3f18ed3b0f44bb7bd18790cbe50b31c
work_keys_str_mv	AT takutohamaoka differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT hisayoshimurai differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT tadayukihirai differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT hiroyukisugimoto differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT yusukemukai differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT otoinoue differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT shinichirotakashima differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT takeshikato differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT shigeotakata differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT soichirousui differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT kenjisakata differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT masaakikawashiri differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure AT masayukitakamura differentresponsesofmusclesympatheticnerveactivitytodapagliflozinbetweenpatientswithtype2diabeteswithandwithoutheartfailure
_version_	1718426575624470528

Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure

Ejemplares similares